iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 4.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 56,507 shares of the company’s stock after selling 2,333 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in iTeos Therapeutics were worth $577,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ITOS. Clearline Capital LP purchased a new stake in shares of iTeos Therapeutics in the 2nd quarter valued at approximately $2,328,000. Algert Global LLC grew its position in iTeos Therapeutics by 92.0% in the third quarter. Algert Global LLC now owns 256,139 shares of the company’s stock worth $2,615,000 after acquiring an additional 122,730 shares during the period. Candriam S.C.A. purchased a new position in iTeos Therapeutics in the second quarter worth approximately $7,558,000. Dimensional Fund Advisors LP increased its stake in iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after acquiring an additional 117,159 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in iTeos Therapeutics by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company’s stock valued at $2,268,000 after purchasing an additional 8,397 shares during the period. 97.16% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Trading Up 2.8 %

Shares of NASDAQ ITOS opened at $7.42 on Friday. The stock has a market capitalization of $271.08 million, a PE ratio of -2.36 and a beta of 1.37. iTeos Therapeutics, Inc. has a twelve month low of $7.09 and a twelve month high of $18.75. The stock has a fifty day simple moving average of $8.54 and a 200-day simple moving average of $12.65.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. On average, equities analysts predict that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current year.

Insider Activity

In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on ITOS. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a research note on Friday, December 13th.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.